SCHEDULE: Wellington Management Discloses Spruce Biosciences Stake

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 3.6% of Spruce Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, has filed an amended Schedule 13G.
• The filing indicates that as of March 31, 2026, these entities collectively beneficially own 48,796 shares of Spruce Biosciences, Inc. common stock.
• This ownership represents approximately 3.6% of the class of securities.
• The securities are held by clients of Wellington investment advisers, with Wellington Investment Advisors Holdings LLP controlling the advisers.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It confirms an institutional investor's stake but provides no new operational or financial information about the company itself.

Positives

• Significant institutional investor (Wellington Management) holds a stake in Spruce Biosciences, Inc.
• The filing confirms a beneficial ownership of 3.6% as of March 31, 2026, indicating continued investment interest.

Negatives

• The filing does not contain financial performance data or operational updates for Spruce Biosciences, Inc., making it difficult to assess the company's health.
• The ownership percentage is relatively small (3.6%), suggesting Wellington Management is not a controlling shareholder.

Risks

• The filing is a Schedule 13G, which is an informational filing by passive investors and does not inherently disclose company-specific risks.
• Potential risks for Spruce Biosciences, Inc. would be detailed in other SEC filings (e.g., 10-K, 10-Q) not provided here.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Spruce Biosciences, Inc. It is a disclosure of beneficial ownership by Wellington Management.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large investment management firms like Wellington Management, indicating their role as asset managers for various clients. The filing signifies their investment in Spruce Biosciences, Inc., but without further context from Spruce Biosciences' own disclosures, it's difficult to ascertain the strategic implications for the company.

Stakeholder Impact

• Shareholders: The filing confirms the presence of a significant institutional investor, which can be viewed positively by other shareholders as it may indicate confidence in the company's long-term prospects.
• Management and Employees: The filing does not directly impact management or employees, other than reinforcing the company's position within the investment community.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Wellington Management will continue to hold its shares in Spruce Biosciences, Inc. as per its investment strategy.
• Spruce Biosciences, Inc. will continue its operations and future disclosures will provide updates on its performance and strategy.

Key Dates

Keywords

Spruce Biosciences, Schedule 13G, Wellington Management, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock